CAMBRIDGE, Mass.--(BUSINESS WIRE)--Xanthus Pharmaceuticals, Inc. today announced the presentation of Phase 1 data from a study of P2045 conducted by Bayer Schering Pharma AG (formerly Schering AG) in patients with advanced lung cancer. The Company holds an exclusive license to P2045 from Schering AG. The presentation was made in a poster session at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). In the study, a single dose of P2045 was well tolerated and patient survival was encouraging.
